ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Hovione Reports Successful End-of-Phase 2 Meeting With the FDA
September 25, 2019Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea. -
Hovione Announces Successful End-of-Phase 2 Meeting with the FDA
September 23, 2019Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
Pharma Sources Insight January 2025
